Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Peter L. Greenberg(University of Colorado Denver), Richard M. Stone(Jewish Hospital), Aref Al‐Kali(Moffitt Cancer Center), Stefan K. Barta, Rafael Bejar(Yale Cancer Center), John M. Bennett, Hetty E. Carraway(University of Colorado Denver), Carlos M. de Castro(University of Colorado Denver), H. Joachim Deeg, Amy E. DeZern(University of Wisconsin Carbone Cancer Center), Amir T. Fathi(University of Colorado Cancer Center), Olga Frankfurt, Karin Gaensler(University of Wisconsin Carbone Cancer Center), Guillermo Garcia‐Manero(University of Colorado Cancer Center), Elizabeth A. Griffiths(University of Wisconsin Carbone Cancer Center), David Head, Ruth Horsfall, Robert A. Johnson, Mark Juckett, Virginia M. Klimek, Rami S. Komrokji, Lisa Kujawski, Lori J. Maness(Yale Cancer Center), Margaret O’Donnell(University of Colorado Denver), Daniel A. Pollyea, Paul J. Shami(University of Colorado Cancer Center), Brady L. Stein(University of Wisconsin Carbone Cancer Center), Alison R. Walker(Jewish Hospital), Peter Westervelt, Amer M. Zeidan, Dorothy A. Shead, Courtney Smith
Cited by 295
Abstract
The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, low-intensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches.
Related Papers
No related papers found
Powered by citation graph analysis